GlassScriptPhysician profile
Lydia H Ferrell
NPI 1760476071
$1,691.82
in general payments reported to CMS, 2019-2025
27 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $167 · 2021: $220 · 2022: $375 · 2023: $182 · 2024: $295 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $210.53 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $209.24 | 2021-2025 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.51 | 2020-2025 | Relistor |
| Pfizer INC. | $166.89 | 2019-2024 | |
| Abbvie INC. | $119.02 | 2022-2024 | |
| Lilly USA, LLC | $117.93 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.92 | 2022 | |
| Amgen INC. | $60.18 | 2019 | |
| Orexo US, INC. | $59.56 | 2019-2023 | Zubsolv |
| Arbor Pharmaceuticals, INC. | $49.99 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $49.45 | 2024 | Horizant |
| Boston Scientific Corporation | $48.28 | 2021-2024 | |
| Vertical Pharmaceuticals, LLC | $40.94 | 2019 | |
| Medtronic USA, INC. | $33.39 | 2019 | |
| Indivior INC. | $32.06 | 2024-2025 | Sublocade |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $31.45 | 2021 | |
| Tersera Therapeutics LLC | $26.05 | 2019 | |
| Shionogi INC | $22.93 | 2019 | |
| Eisai INC. | $22.08 | 2021 | |
| Horizon Therapeutics Plc | $19.63 | 2021 | |
| Abbott Laboratories | $19.35 | 2024 | Proclaim |
| Smith+Nephew, INC. | $16.12 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.08 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.63 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $13.04 | 2021 | |
| Daiichi Sankyo INC. | $12.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.